IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Michael Yeadon

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned

:Group Art Unit: To Be Assigned

TITLE: Pharmaceutical Combination

Commissioner for Patents

FILING DATE: Herewith

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: December 16, 200

Robert T. Ronau

Attorney for Applicant(s)

Reg. No. 36,257

Pfizer Inc.

Patent Department, Box 8260-1611

Eastern Point Road Groton, CT 06340 (860) 441-5910

EXPRESS MAIL NO. 5027 1824743US

															
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 1 of 1							TY. DOC	KET N	O. PC22050B	<u> </u>	SERIAL NO). To Be A	ssign	ed	
							APPLICANT Michael Yeadon								
							ING DA	TE Her	ewith		GROUP To Be Assigned				
						U.S	. PATEN	IT DOC	UMENTS						
EXAMINER INITIAL				DOC	UMENT NUMB	ER	•		DATE	NAME	CLASS	SUBCLASS	FILING IF APPR	G DATE ROPRIATE	
INITIAL								l	†	 			1		
													 		
										-			 		
												 	\vdash	_	
													+	_	
										-					
	$\perp \perp$														
					-								—		
	<u>ll</u> ,			<u> </u>		005	011 047	· · · · · ·	0011151150				<u> </u>		
			DC	CUMENT NU		ORE	GN PAI	ENID	OCUMENTS DATE	COUNTRY	/ CLASS	SUBCLASS	TRANS	SLATION	
					, moen				DATE	COUNTRI	CLASS	SUBCLASS	YES	NO	
	wo	9	6	3	9	4	0	3	12 Dec 96	Internation	nal C07D	471/14			
	wo	0	1	1	3	9	5	3	1 March 01	Internation	nal A61K	45/06			
	wo	0	0	1	2	0	7	8	9 March 00	Internation	nal A61K	31/19	—	ļ	
				<u> </u>	+ +			 	 				 	├—	
					1				<u> </u>			+	╁	-	
		-						†					1	\vdash	
									<u> </u>						
			 		-		· · · · · · · · · · · · · · · · · · ·	ļ					 	—	
	╁			<u> </u>	+ +			 				 	 	₩	
					† †		 	 	 			+	+		
									<u> </u>				\vdash	\vdash	
			-		 			 					<u> </u>	ļ	
			071					<u> </u>	<u> </u>				<u> </u>	<u> </u>	
		Tomb			ealth Persp				Title, Date, Pe	ertinent Pag	ges, Etc.)				
					Chem. 39,	_		10, 79-64	, 1994			*			
					acol. Bioche				995						
					Pharmacol nacol. Exp.										
		Wrigh	t et al., C	an. J. Ph	ysiol. Pham	nacol.,	75, 1001-	1008, 199							
	-				narmacol. 3										
 					m., 42, 108 Pharm. Desi			5-1296							
						J ., = J	_, , , , , , , ,								
EXAMINE	:D							DATE	CONCIDENTE						
									CONSIDERED						
EXAMINER: next commun	Initial if re lication to	ference con applicant,	sidered, wh	ether or not o	citation is in cor	nformano	e with MPEP	609; Draw lir	ne through citation if ne	ot in conformance	and not considered	l. Include copy of	this form	with	